FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Target Recruit Count
- 30
- Registration Number
- NCT03171831
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 123
- Registration Number
- NCT03156452
- Locations
- 🇬🇧
University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Conditions
- Interventions
- Drug: BusulfanDrug: CyclophosphamideDrug: Fludarabine PhosphateProcedure: Hematopoietic Cell TransplantationOther: Laboratory Biomarker AnalysisDrug: Melphalan HydrochlorideDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT03128359
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT03128034
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT03121001
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT03118492
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03108274
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT03099122
- Locations
- 🇨🇳
CHINA, China, China
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Conditions
- Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeLangerhans Cell HistiocytosisAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaNon-Hodgkin LymphomaRecurrent Hodgkin LymphomaTherapy-Related Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03096782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 5
- Registration Number
- NCT03088709
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.